Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Get a feel for Oncodesign’s energy through relevant information about our business!
News comes to you with regular newsletters and news, teeming with vitality and ingenuity!
Customers and partners, stay in the loop about our progress for our discoveries as well as new developments related to our service offers by subscribing to our newsletter at the heart of our Services activity.
Investors and financial professionals, don’t miss out on any of Oncodesign’s financial news. Stay at the heart of our company with all our financial news, including our biannual letter to shareholders. We prepare all the information you could ever be interested in so you don’t have to!
18 rue Jean Mazen - FR - 21000 Dijon Tel.+33 380 788 260